Microcap Ledger Relmada Therapeutics, Inc. $RLMD
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Coral Gables, FL
- Fiscal year end
- December 31
- Shares outstanding
- 106,669,846 [10-Q 2026-08-06]
What the company doesAI summary of filing
Relmada Therapeutics is a clinical-stage biotechnology company with no approved products or revenue. The company develops drug candidates for cancer and neurological disorders. Its lead product, NDV-01, is a controlled-release formulation of gemcitabine and docetaxel in Phase 2 clinical trials for non-muscle-invasive bladder cancer; the company expects to initiate Phase 3 trials in mid-2026. Its second product, sepranolone, is a neurosteroid in Phase 2b development for Prader-Willi syndrome, Tourette Syndrome, essential tremor, and other neurological conditions; Phase 2 trials in Prader-Willi syndrome are expected to begin mid-2026. The company generates no revenue and reported net losses of $57.4 million and $80.0 million for 2025 and 2024, respectively. [10-K 2026-03-19]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$31.97M | −$24.67M | $11.33M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | — | $0.00 | −$45.79M | $3.50M | [DEF 14A 2026-04-17] |
| FY ended Dec 2024 | — | $0.00 | −$51.76M | $3.86M | [DEF 14A 2026-04-17] |
- Quarterly cash burn
- −$12.34M
- Cash runway Estimate
- ~2.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 30,174,202 | [10-Q 2024-11-07] |
| 2025-03-25 | 33,191,622 | [10-K 2025-03-27] |
| 2025-05-07 | 33,191,622 | [10-Q 2025-05-12] |
| 2025-08-04 | 33,191,622 | [10-Q 2025-08-07] |
| 2025-11-10 | 73,333,622 | [10-Q 2025-11-13] |
| 2026-03-16 | 104,890,223 | [10-K 2026-03-19] |
| 2026-05-07 | 104,890,223 | [10-Q 2026-05-12] |
| 2026-08-04 | 106,669,846 | [10-Q 2026-08-06] |
- Shelf registration
- S-3ASR filed 2026-05-13 [S-3ASR 2026-05-13]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-07-23. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-07-23 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-07-23] |
| 2025-01-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-27] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-10 | Shenouda Maged | buy | 79,800 | $4.25 | [4 2026-09-11] |
| 2026-09-10 | Traversa Sergio | buy | 100,000 | $4.10 | [4 2026-09-11] |
| 2026-09-09 | Shenouda Maged | buy | 120,200 | $4.20 | [4 2026-09-11] |
| 2026-09-09 | Traversa Sergio | buy | 100,000 | $4.18 | [4 2026-09-11] |
| 2025-12-15 | Traversa Sergio | buy | 27,500 | $4.12 | [4 2025-12-16] |
| 2025-12-15 | Shenouda Maged | buy | 11,665 | $4.12 | [4 2025-12-16] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-08 | 8-K | Other events |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-07-29 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-28 | 8-K | Regulation FD disclosure |
| 2026-06-22 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-09 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-28 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-05-13 | S-3ASR | Registration statement |
| 2026-05-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | 8-K | Results of operations; Regulation FD disclosure |
Alerts for $RLMD
Email me when Relmada Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.